U.S. Army to evaluate Ebola vaccine candidates

The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) will test the validity of potential Ebola treatment options as part of an agreement with NanoViricides, Inc., signed on Monday.

The current Ebola outbreak has spurned forward the pressing issue of the lack of a treatment option for this deadly disease. Since December, the outbreak has posted a 70 percent mortality rate and has sent sporadic cases out of Africa.

"We are very happy to restart our collaboration with USAMRIID for developing an effective drug against the deadly Ebola virus," Dr. Eugene Seymour, the CEO of NanoViricides, said. "We intend to ship the samples as soon as the synthesis of the new drug candidates is completed."

NanoViricides intends to meet research goals on a "war-like" timeline and hopes to create a viable compound rapidly. Its potential treatment options mimic cell receptors that the virus uses to attach itself. The company stresses that this has not changed with different mutations, which is where other potential vaccines fail when the different strains mutate to overcome antibodies and potential vaccines.

Organizations in this story

U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) 1425 Porter Street Frederick, MD 21702-5011

Get notified the next time we write about U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)!